News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
259,232 Results
Type
Article (13835)
Company Profile (293)
Press Release (245104)
Section
Business (79312)
Career Advice (147)
Deals (13180)
Drug Delivery (31)
Drug Development (50265)
Employer Resources (31)
FDA (5669)
Job Trends (5110)
News (144035)
Policy (10017)
Tag
Academia (901)
Alliances (21444)
Alzheimer's disease (731)
Approvals (5633)
Artificial intelligence (61)
Bankruptcy (97)
Best Places to Work (4468)
Biotechnology (241)
Breast cancer (57)
Cancer (603)
Cardiovascular disease (52)
Career advice (128)
CAR-T (48)
Cell therapy (156)
Clinical research (39608)
Collaboration (205)
Compensation (85)
COVID-19 (998)
C-suite (58)
Cystic fibrosis (61)
Data (641)
Diabetes (65)
Diagnostics (1191)
Earnings (28686)
Events (46607)
Executive appointments (157)
FDA (5918)
Funding (211)
Gene editing (51)
Gene therapy (130)
GLP-1 (292)
Government (1064)
Healthcare (6528)
Infectious disease (1028)
Inflammatory bowel disease (89)
IPO (7171)
Job creations (859)
Job search strategy (124)
Layoffs (182)
Legal (1374)
Lung cancer (102)
Manufacturing (68)
Medical device (2547)
Medtech (2548)
Mergers & acquisitions (6092)
Metabolic disorders (204)
Neuroscience (913)
NextGen Class of 2024 (1998)
Non-profit (843)
Northern California (812)
Obesity (117)
Opinion (90)
Parkinson's disease (55)
Patents (47)
People (24902)
Pharmaceutical (48)
Phase I (13924)
Phase II (18414)
Phase III (11689)
Pipeline (168)
Postmarket research (846)
Preclinical (5885)
Radiopharmaceuticals (203)
Rare diseases (144)
Real estate (1409)
Regulatory (8167)
Research institute (930)
Southern California (751)
Startups (1963)
United States (6798)
Vaccines (154)
Weight loss (74)
Date
Today (134)
Last 7 days (536)
Last 30 days (1927)
Last 365 days (20592)
2024 (17942)
2023 (22412)
2022 (26822)
2021 (27807)
2020 (23359)
2019 (16228)
2018 (11741)
2017 (13747)
2016 (11840)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7429)
Location
Africa (146)
Asia (16774)
Australia (2821)
California (1843)
Canada (656)
China (137)
Colorado (70)
Connecticut (72)
Europe (36110)
Florida (198)
Georgia (53)
Illinois (114)
Indiana (53)
Kansas (54)
Maryland (278)
Massachusetts (1536)
Michigan (45)
Minnesota (83)
New Jersey (497)
New York (552)
North Carolina (384)
Northern California (812)
Ohio (73)
Pennsylvania (386)
South America (207)
Southern California (751)
Texas (192)
Washington State (199)
259,232 Results for "tempest therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Tempest to Participate in Upcoming Investor Conferences - May 21, 2024
Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, announced that management will participate in the following upcoming investor conferences.
May 21, 2024
·
1 min read
Press Releases
Tempest Extends Limited Duration Stockholder Rights Plan
October 11, 2024
·
6 min read
Drug Development
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
Tempest Therapeutics, Inc. announced new positive data from the ongoing global randomized Phase 1b/2 clinical study in which amezalpat2, Tempest’s PPAR⍺ antagonist, delivered a six-month improvement in median overall survival advantage when combined with atezolizumab and bevacizumab in a comparison to atezolizumab and bevacizumab alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma.
June 20, 2024
·
9 min read
Business
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, reported financial results for the quarter ended March 31, 2024, and provided a corporate update.
May 9, 2024
·
8 min read
Biotech Bay
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 07, 2024
Tempest Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 14,000 shares of its common stock under the Company’s 2023 Inducement Plan.
June 7, 2024
·
1 min read
Drug Development
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
Tempest Therapeutics, Inc. announced the company plans to report new data from the global randomized Phase 1b/2 combination study of amezalpat with atezolizumab and bevacizumab in first-line treatment of hepatocellular carcinoma in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.m. ET.
June 18, 2024
·
1 min read
Biotech Bay
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
Tempest Therapeutics, Inc. announced that Stephen Brady, president and chief executive officer of Tempest, will present at the 44th Annual TD Cowen Healthcare Conference on Monday, March 4, 2024 at 9:10 a.m. ET.
February 26, 2024
·
1 min read
Business
Tempest Reports Year End 2023 Financial Results and Provides Business Update
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the year ended 2023 and provided a corporate update.
March 19, 2024
·
10 min read
Press Releases
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
October 11, 2024
·
7 min read
Biotech Bay
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 26, 2024
Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 5,400 shares of its common stock under the Company’s 2023 Inducement Plan.
April 26, 2024
·
1 min read
1 of 25,924
Next